AR117406A1 - PARENTERAL PHARMACEUTICAL COMPOSITION - Google Patents

PARENTERAL PHARMACEUTICAL COMPOSITION

Info

Publication number
AR117406A1
AR117406A1 ARP190100736A ARP190100736A AR117406A1 AR 117406 A1 AR117406 A1 AR 117406A1 AR P190100736 A ARP190100736 A AR P190100736A AR P190100736 A ARP190100736 A AR P190100736A AR 117406 A1 AR117406 A1 AR 117406A1
Authority
AR
Argentina
Prior art keywords
parenteral pharmaceutical
treatment
pharmaceutical composition
patients
neladenosone
Prior art date
Application number
ARP190100736A
Other languages
Spanish (es)
Inventor
Pfeffer Michael Dr
Nicolai Janine Dr
Anlahr Johanna Dr
Erber Matthias Christian Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR117406A1 publication Critical patent/AR117406A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas parenterales que comprenden L-alanil-L-alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etilo, que también se conoce como bialanato de neladenosona, en forma de una de sus sales, un proceso para su preparación, su uso como medicamento, así como su uso para la prevención y/o el tratamiento de enfermedades cardiovasculares, por ejemplo para cardioprotección durante, y/o después de un evento cardíaco inducido por isquemia, por ejemplo después de una cirugía no cardíaca de mediano y alto riesgo, lesión por reperfusión en pacientes de STEMI, y tratamiento de pacientes agudos hospitalizados con empeoramiento de la insuficiencia cardíaca.Parenteral pharmaceutical compositions comprising 2- {4- [2 - ({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} sulfanyl) -3.5 L-alanyl-L-alaninate -diciano-6- (pyrrolidin-1-yl) pyridin-4-yl] phenoxy} ethyl, which is also known as neladenosone biathanate, in the form of one of its salts, a process for its preparation, its use as a medicine, as well as its use for the prevention and / or treatment of cardiovascular diseases, for example for cardioprotection during, and / or after a cardiac event induced by ischemia, for example after a non-cardiac surgery of medium and high risk, injury by reperfusion in STEMI patients, and treatment of acute hospitalized patients with worsening heart failure.

ARP190100736A 2018-03-22 2019-03-22 PARENTERAL PHARMACEUTICAL COMPOSITION AR117406A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18163467 2018-03-22

Publications (1)

Publication Number Publication Date
AR117406A1 true AR117406A1 (en) 2021-08-04

Family

ID=61763827

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100736A AR117406A1 (en) 2018-03-22 2019-03-22 PARENTERAL PHARMACEUTICAL COMPOSITION

Country Status (2)

Country Link
AR (1) AR117406A1 (en)
WO (1) WO2019180072A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE102009006602A1 (en) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
EP2389923B1 (en) 2010-05-19 2013-01-30 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
CN107531688A (en) 2015-05-06 2018-01-02 拜耳制药股份公司 For preparing { 4 [2 ({ [2 (4 chlorphenyls) 1 of L alanyl L alanine 2, the base of 3 thiazole 4] methyl sulfanyl) 3,5 dicyano 6 (base of pyrrolidines 1) pyridine, 4 base] phenoxy group ethyl ester monohydrochloride method

Also Published As

Publication number Publication date
WO2019180072A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
CL2010001636A1 (en) (r, z) -5- (2- (3-aminopiperidin-1-yl) -3-isopropoxybenzylidene) thiazolidin-2,4-dione, (r, z) -5- (2- (3-aminopiperidin-1 -il) biphenyl-3-ylmethylene) thiazolidin-2,4-dione, or a salt thereof; pharmaceutical composition; use for the treatment of cancer and for the inhibition of pim kinase.
UY31244A1 (en) DIPEPTOID PROFARMS AND ITS USE
JP2015057427A5 (en)
BR112017024933A8 (en) ALVOCIDIB PRODUCE WITH INCREASED BIOAVAILABILITY
AR112284A1 (en) COMBINATION INCLUDING PALBOCICLIB AND ACID 6- (2,4-DICHLOROPHENIL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-IL] OXIPHENIL] -8,9-DIHIDRO-7H- BENZO [7] ANNULENE-2-CARBOXYL
MX2023012450A (en) Esketamine for the treatment of depression.
CL2021002963A1 (en) Novel crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for cancer treatment
AR074471A1 (en) COMPOUND 5 (5- (2- (3-AMINOPROPOXI) - 6 - METOXIFENIL) -1H- PIRAZOL-3- ILAMINO) PIRAZIN -2-CARBONITRILE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICATION TO INHIBIT CHK1 AND TO TREAT CANCER
EA201892746A1 (en) TREATMENT OF HEMATOLOGICAL MALIGNANT TUMOR WITH THE HELP OF 2- (4-CHLOROPHENIL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXYDISOINDOLIN-5-IL) METHYL -2-2-IL) -1-OXYDISOINDOLIN-5-IL) METILE-2-IL-1-IL) -1-OXYDISOINDOLIN-5-IL) METILE-2-IL-1-IL) -1-OXYDISOINDOLIN-5-IL) METHYL 2-2-IL-1-OXYDISOINDOLIN-5-IL-ILE-2-2-IL-1-OXO-ISOINDOLIN-5-IL-ILE-2-2-IL-1-OXO-ISOINDOLIN-5-IL-ILE-2-2-IL-1-OXY-ISO-DYNDOLIN-5-IL-I-3-OXYDE
CR20190200A (en) 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma
BR112017004173A2 (en) compound, pharmaceutical composition, and method for treating a disease or condition.
MX2015013893A (en) Novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient.
CO2018002708A2 (en) Therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity-related disorders
CO2021013251A2 (en) Glucose-sensitive insulin derivatives
BR112021024325A2 (en) 3-(5-Methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide analogues
RU2017120858A (en) SUBSTITUTED URINE ANALOGUES WITH BRIDGE COMMUNICATION AS SIRTUIN MODULATORS
AR093188A1 (en) SALT AND MEDICAL USE
AR117406A1 (en) PARENTERAL PHARMACEUTICAL COMPOSITION
PE20180204A1 (en) PROCEDURE FOR THE PREPARATION OF 2-4- [2 - ([2- (4- (CHLOROPHENIL) -1,3-THIAZOL-4-IL] METHYLSULFANIL) -3,5-DICIANE-6- (PYRROLIDIN-1-IL ) PYRIDINE-4-IL] PHENOXYETHYL-L-ALANIL-L-ALANINATE-MONOHYDROCHLORIDE
AR102248A1 (en) AROMATIC COMPOUNDS REPLACED AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES
BR112017012965A2 (en) fumagilol derivatives
WO2017220051A3 (en) Benserazide hydrochloride pharmaceutical composition and medical use thereof for lowering blood sugar
Arnolds et al. Comment on Retnakaran et al. Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014; 37: 3270–3278
AR121038A1 (en) GLUCOSE-SENSITIVE INSULIN DERIVATIVES
AR120578A1 (en) BENZYLAMIDE DERIVATIVES AS TRANSFORMING GROWTH FACTOR b1 (TGFbRI)/ALK5 RECEPTOR INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure